Summary

Treatment of chronic bronchopulmonary infection by Pseudomonas aeruginosa in patients with cystic fibrosis (CF) with liposomal amikacin for inhalation (LAI) resulted in improved pulmonary function and decreased P aeruginosa sputum concentration in an interim analysis. This article discusses interim data from the Long Term Safety and Tolerability of Open-Label Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients With Chronic Infection due to Pseudomonas aeruginosa trial [CLEAR-110; NCT01316276; Bilton D et al. Am J Respir Crit Care Med 2014].